Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05574010 · ClinicalTrials.gov registry record · Phase 1
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
A Phase 1 study, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
- Terminated
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT05574010 is a Phase 1 study that was terminated before completion, run by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion. The registered enrollment target is 128 participants.
The verdict
NCT05574010, a Phase 1 study, was terminated before completion, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).
Interventions
- DRUG Cohort 1 in Part A
- DRUG Cohort 2 in Part A
- OTHER Placebo: Group 1 in Part B and Part C
- DRUG Group 2 in Part B and Part C
- DRUG Group 3 in Part B and Part C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2025-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05574010
The ClinicalTrials.gov registry entry for NCT05574010 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cohort 1 in Part A is the first listed.
NCT05574010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05574010 about?
NCT05574010 is a clinical study titled "A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)". This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).
What is the current status of trial NCT05574010?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2022-11-15. Estimated completion is 2025-05-19.
What interventions are being tested in trial NCT05574010?
The interventions under investigation include: Cohort 1 in Part A (DRUG), Cohort 2 in Part A (DRUG), Placebo: Group 1 in Part B and Part C (OTHER), Group 2 in Part B and Part C (DRUG), Group 3 in Part B and Part C (DRUG).
Who is sponsoring clinical trial NCT05574010?
This trial is sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.